The APS system comes equipped with filter switching, liquid management, and cell bleed to reduce risk of human error and increase process robustness.
Cytiva announced on Sept. 16, 2020 that it is launching the Xcellerex Automated Perfusion System (APS), a device aimed at simplifying processes and reducing risks when intensifying upstream operations.
Integrated with Cytiva’s Xcellerex XDR bioreactors, the APS system comes equipped with filter switching, liquid management, and cell bleed to reduce risk of human error and increase process robustness, a company press release said. The system also eliminates bottlenecks along the perfusion process, which increases productivity and output.
“Simplifying upstream bioprocess workflows is one way we deliver on Cytiva’s mission to advance and accelerate therapeutics,” said Olivier Loeillot, senior vice-president BioProcess, Cytiva, in the press release. “Along with our end-to-end flexible manufacturing solutions, automation technology, and trusted expertise, we have introduced Xcellerex APS to support the industry’s journey to integrated continuous manufacturing.”
Source: Cytiva